TREATMENT GUIDELINES AND REFERENCES

PLEASE NOTE: This information is only intended for use by Physicians. To view the files you must have Adobe Reader.
To download a free copy of this program visit www.adobe.com.

Langerhans cell histiocytosis


(LCH III protocol is closed to new patients in North America)


LCH III Progress Report - North America

LCH III Progress Report - all other countries

Scientific Review of LCH II Manuscript

Standard of Care LCH Treatment Guidelines


Further reading/reference:

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. 

Gadner H, Grois N, Pötschger U, Minkov M, Aricò M, Braier J, Broadbent V, Donadieu J, Henter JI, McCarter R, Ladisch S; Histiocyte Society. 
Blood. 2008 Mar 1; 111(5):2556-62. Epub 2007 Dec 18.


List of national LCH Study contacts in North America:

Carlos Rodriguez-Galindo, MD
Dana Farber Cancer Institute
Director of the Solid Tumor Program
44 Binney St
Shileds Warren 350
Boston, MA 02115 USA
Phone: +1 617 632 4580
Email: Carlos_Rodriguez-Galindo@dfci.harvard.edu

James A. Whitlock, MD
Division Head, Hematology/Oncology
Women’s Auxiliary Millennium Chair in Haematology/Oncology
Professor of Paediatrics, University of Toronto
The Hospital for Sick Children
Division of Haematology/Oncology
555 University Ave
Toronto, ON M5G 1X8 Canada
Phone: +1 416 813 8885
Fax: +1 416 813 5327
Email: jim.whitlock@sickkids.ca

Kenneth McClain MD, PhD
Texas Children’s Cancer Center and Hematology Service
6701 Fannin St CC 1500, Ste 1410
Houston TX 77030 USA
Phone: +1 832 822 4208
Fax: +1 832 825 1503
Email: klmcclain@txccc.org

Sheila Weitzman, MD
Hospital for Sick Children
555 University Ave
Toronto, M5G 1X8 Ontario Canada
Phone: +1 416 813 5872
Fax: +1 416 813 5327
Email: Sheila.weitzman@sickkids.ca



Outside of North America:

Milen Minkov, MD, PhD
St. Anna Children's Hospital
Kinderspitalgasse 6
Vienna, 1090 Austria
Phone: +43 140 470 4760
Email: milen.minkov@stanna.at

Johannes Visser
University Hospital Leicester
Leicester Royal Infirmary
Leicester, LE142DF United Kingdom
Phone: +01 16 258 5390
Email: johannes.visser@uhl-tr.nhs.uk


Langerhans Cell Histiocytosis Salvage Study

For further information, please contact one of the study coordinators listed below.


Further reading/reference:

Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.

Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M, Colin VM, Perel Y, Chastagner P, Vermylen C, Donadieu J.
Eur J Cancer. 2005 Nov; 41(17):2682-9. Epub 2005 Apr 7


For more information please contact:

Principal Investigator:
Jean Donadieu, MD
Hospital Trousseau
Hematologie-Oncologie
26 Rue Du D Netter
Paris, F-75012 France
Phone: +33 1 44736062
Fax: +33 1 44736573
Email: jean.donadieu@trs.aphp.fr


In North America:

James A. Whitlock, M.D.
Division Head, Hematology/Oncology
Women’s Auxiliary Millennium Chair in Haematology/Oncology
Professor of Paediatrics, University of Toronto
The Hospital for Sick Children
Division of Haematology/Oncology
555 University Ave
Toronto, ON M5G 1X8 Canada
Phone: +1 416 813 8885
Fax: +1 416 813 5327
Email: jim.whitlock@sickkids.ca



Hemophagocytic Lymphohistiocytosis

Standard of Care

A Standard of Care paper is currently being written by the Histiocyte Society.


Clinical Trial HLH 2004: Treatment Protocol of the 2nd International HLH Study


Further reading/references:

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society.
Blood. 2002 Oct 1; 100(7):2367-73.

Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis.

Horne A, Janka G, Maarten Egeler R, Gadner H, Imashuku S, Ladisch S, Locatelli F, Montgomery SM, Webb D, Winiarski J, Filipovich AH, Henter JI; Histiocyte Society.
Br J Haematol. 2005 Jun; 129(5):622-30.


For more information or to obtain the HLH 2004 protocol please contact:

Principal investigator:
Jan-Inge Henter, MD, PhD
Childhood Cancer Research Unit
Karolinska Hospital, Q6:05
Stockholm SE-171 76  Sweden
Phone: +46 8 5177 2536
Fax: +46 8 5177 3184
Email: Jan-Inge.Henter@ki.se


In North America:

Clinical Study Group member:
Alexandra Filipovich, MD
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave
Cincinnati, OH 45229 USA
Phone: +1 513 636 7287
Fax: +1 513 636 5845
Email: Lisa.Filipovich@cchmc.org 



LCH – A1: FIRST INTERNATIONAL STUDY FOR LANGERHANS CELL HISTIOCYTOSIS IN ADULTS

Please contact the principal investigator or the clinical study group leader for questions.


For more information:

Principal investigator
Maurizio Aricó
Azienda Ospedaliero-Universitaria Meyer
Head, Dept. Pediatric Hematology Oncology
Viale Pieraccini 24
Florence 50139, Italy
Phone:  +39 055 566 2739
Fax: +39 055 5662746
Email: m.arico@meyer.it


In North America:

Clinical Study Group member:
Kenneth McClain MD, PhD
Texas Children’s Cancer Center and Hematology Service
6701 Fannin St CC 1500, Ste 1410
Houston TX 77030 USA
Phone:  +1 832 822 4208
Fax: +1 832 825 1503
Email: klmcclain@txccc.org 


Histiocyte Society Membership Information

Histiocyte Society

332 North Broadway - Pitman, NJ 08071
Phone: +1 856.589.6606 | Fax: +1 856.589.6614

Copyright 2011 Histiocyte Society